Sort
48,018 grants matching “immunotherapy”
EPITOPE BASED DNA VACCINES FOR AIDS THERAPY
$1,338,746Idm Pharma, Inc. · P01 · FY2001 · AI
Pediatric AIDS Clinical Trials Unit
$1,338,613Children'S Memorial Hospital (Chicago) · U01 · FY2003 · AI
Immunotherapy to prevent drug-resistant tuberculosis
$1,337,935Rhea N Coler · Access To Advanced Health Institute · R01 · FY2018 · AI
PEDIATRIC ACTG - ACTU
$1,336,540University Of Miami School Of Medicine · U01 · FY2000 · AI
Thoracic and Gastrointestinal Malignancies Branch Clinical Core
$1,336,014Raffit Hassan · Division Of Basic Sciences - Nci · ZID · FY2019 · CA
Novel approaches to cancer therapy
$1,333,893University Of Pennsylvania · P01 · FY2004 · CA
Virus and Host Directed Immunotherapies for Cure in SHIV-infected Infant Macaques
$1,332,155Ann M Chahroudi · Emory University · R01 · FY2025 · AI
Cancer-cell specific therapy: photo-immunotherapy
$1,332,032Hisataka Kobayashi · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
$1,331,718University Of Texas Sw Med Ctr/Dallas · U01 · FY2004 · AI
The effect of peptide therapy and allergen provocation on Fel d1-specific T Cells
$1,330,917Mark Larche · Mcmaster University · U19 · FY2012 · AI
Translational Studies in Progressive Multifocal Leukoencephalopathy
$1,330,691Irene Cortese · National Institute Of Neurological Disorders And Stroke · ZIA · FY2022 · NS
Improving the Outcome of Patients with Chronic Myeloid Leukemia Through Medi
$1,330,233Jorge E Cortes · University Of Tx Md Anderson Can Ctr · P01 · FY2011 · CA
Novel Targets for Immunotherapy
$1,330,078Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA
Point-of-care antimicrobial susceptibility testing based on simultaneous tracking of multi-phenotypic features of single bacterial cells
$1,329,765Nongjian Tao · Arizona State University-Tempe Campus · R01 · FY2018 · AI
Clinical Development of Novel Therapies for Acute Lymphoblastic Leukemia
$1,329,439Nirali Shah · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$1,328,788Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Immune Regulation in Mycobacterial and Fungal Infections
$1,328,731Daniel Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
MODULATION OF EFFECTOR T CELLS IN DIABETES
$1,328,138Scripps Research Institute · P01 · FY2001 · DK
MODULATION OF EFFECTOR T CELLS IN DIABETES
$1,328,138Scripps Research Institute · P01 · FY2000 · DK
IL-27R signaling as a negative regulator of innate and adaptive anti-cancer immunity in hepatocellular carcinoma
$1,327,850Ekaterina Koltsova · Cedars-Sinai Medical Center · R01 · FY2025 · CA
Novel Target, New Therapy: Anti- Renalase Antibody for Tumors Resistant to PD-1Inhibitors
$1,327,758Barry A Berkowitz · Bessor Pharma, Llc · R44 · FY2021 · CA
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma
$1,327,446Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Cancer Vaccines and Immunotherapy
$1,327,187Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Clinical Trials of Patients with AIDS-Related Malignancies
$1,325,644Robert Yarchoan · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Immunotherapy of low grade lymphoid malignancies
$1,324,138Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2018 · HL